ArticleCureus2026
Prognostic Value of the Pre-treatment Albumin-to-Alkaline Phosphatase Ratio in Patients With Metastatic Colorectal Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Value of the Royal Marsden Hospital Score in Patients with De Novo Metastatic Colorectal Cancer Receiving First-Line Systemic Therapy.Journal of clinical medicine · 2026Article
- Exploratory Development and Interpretation of an Internally Validated XGBoost-Cox Model Based on Preoperative Inflammation-Nutrition Indices for Overall Survival in Primary Pathological Stage I Rectal Cancer.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the prognostic significance of the albumin-to-alkaline phosphatase ratio (AAPR) in patients with metastatic colorectal cancer (mCRC) and compare it with the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in the same patient cohort.
methodsThis retrospective study included patients who were followed for mCRC and whose pre-treatment albumin, alkaline phosphatase (ALP), NLR, and PLR values were obtained. Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal AAPR, NLR, and PLR cut-off values.
resultsThis study included 182 patients. The patients' median age was 57 (18-87) years, 110 (60.4%) were men, 162 (89%) had de novo metastatic disease, and 75 (41.2%) had right colon cancer. ROC analysis for the pre-treatment AAPR value of OS yielded an AUC of 0.622 (95% confidence interval (CI): 0.548-0.693, p=0.040), and the optimal AAPR cut-off value was ≤0.323. The median AAPR was lower in patients with liver metastasis than in those without (p=0.018) and in de novo metastatic patients than in recurrent patients (p=0.001). Median progression-free survival was longer in recurrent patients than in de novo metastatic patients (11 vs. 7 months, p=0.018). Univariate analysis showed that the AAPR significantly predicted OS (hazard ratio: 0.23,95% CI: 0.08-0.62, p=0.004), whereas NLR and PLR did not (p=0.718 and p=0.403, respectively). Median OS was 16 months (95% CI: 12.7-19.3) in all patients, 11 (95% CI: 7.5-14.5) months in the low-AAPR group, and 21 (95% CI: 17.4-24.6) months in the high-AAPR group (p=0.008).
conclusionIn patients with mCRC, the OS was worse in the low-AAPR group than in the high-AAPR group. The AAPR showed a stronger univariable association with OS than NLR/PLR in this cohort, but did not retain independent significance in multivariable analysis; prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.